冠心病中的动机性访谈与药物评估(MIMeRiC):干预措施开发及过程评估方案
Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Intervention Development and Protocol for the Process Evaluation.
作者信息
Östbring Malin Johansson, Eriksson Tommy, Petersson Göran, Hellström Lina
机构信息
Pharmaceutical Department, Kalmar County Council, Kalmar, Sweden.
eHealth Institute, Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden.
出版信息
JMIR Res Protoc. 2018 Jan 30;7(1):e21. doi: 10.2196/resprot.8660.
BACKGROUND
Trials of complex interventions are often criticized for being difficult to interpret because the effects of apparently similar interventions vary across studies dependent on context, targeted groups, and the delivery of the intervention. The Motivational Interviewing and Medication Review in Coronary heart disease (MIMeRiC) trial is a randomized controlled trial (RCT) of an intervention aimed at improving pharmacological secondary prevention. Guidelines for the development and evaluation of complex interventions have recently highlighted the need for better reporting of the development of interventions, including descriptions of how the intervention is assumed to work, how this theory informed the process evaluation, and how the process evaluation relates to the outcome evaluation.
OBJECTIVE
This paper aims to describe how the intervention was designed and developed. The aim of the process evaluation is to better understand how and why the intervention in the MIMeRiC trial was effective or not effective.
METHODS
The research questions for evaluating the process are based on the conceptual model of change processes assumed in the intervention and will be analyzed by qualitative and quantitative methods. Quantitative data are used to evaluate the medication review in terms of drug-related problems, to describe how patients' beliefs about medicines are affected by the intervention, and to evaluate the quality of motivational interviewing. Qualitative data will be used to analyze whether patients experienced the intervention as intended, how cardiologists experienced the collaboration and intervention, and how the intervention affected patients' overall experience of care after coronary heart disease.
RESULTS
The development and piloting of the intervention are described in relation to the theoretical framework. Data for the process evaluation will be collected until March 2018. Some process evaluation questions will be analyzed before, and others will be analyzed after the outcomes of the MIMeRiC RCT are known.
CONCLUSIONS
This paper describes the framework for the design of the intervention tested in the MIMeRiC trial, development of the intervention from the pilot stage to the complete trial intervention, and the framework and methods for the process evaluation. Providing the protocol of the process evaluation allows prespecification of the processes that will be evaluated, because we hypothesize that they will determine the outcomes of the MIMeRiC trial. This protocol also constitutes a contribution to the new field of process evaluations as made explicit in health services research and clinical trials of complex interventions.
背景
复杂干预试验常因难以解读而受到批评,因为看似相似的干预措施在不同研究中的效果因背景、目标群体和干预实施方式而异。冠心病动机性访谈与药物评估(MIMeRiC)试验是一项随机对照试验(RCT),旨在改善药物二级预防。近期,关于复杂干预措施开发与评估的指南强调,需要更好地报告干预措施的开发情况,包括对干预措施作用机制的描述、该理论如何为过程评估提供指导,以及过程评估与结果评估的关系。
目的
本文旨在描述干预措施的设计与开发过程。过程评估的目的是更好地理解MIMeRiC试验中的干预措施为何有效或无效。
方法
评估过程的研究问题基于干预措施中假设的变化过程概念模型,将通过定性和定量方法进行分析。定量数据用于从药物相关问题的角度评估药物评估,描述患者对药物的信念如何受到干预措施的影响,以及评估动机性访谈的质量。定性数据将用于分析患者是否按预期体验了干预措施、心脏病专家如何体验协作与干预措施,以及干预措施如何影响患者冠心病后的整体护理体验。
结果
干预措施的开发与试点情况结合理论框架进行了描述。过程评估数据将收集至2018年3月。部分过程评估问题将在MIMeRiC随机对照试验结果知晓之前进行分析,其他问题将在结果知晓之后进行分析。
结论
本文描述了MIMeRiC试验中所测试干预措施的设计框架、从试点阶段到完整试验干预措施的开发过程,以及过程评估的框架和方法。提供过程评估方案可预先确定将评估的过程,因为我们假设这些过程将决定MIMeRiC试验的结果。该方案也为卫生服务研究和复杂干预措施临床试验中明确阐述的过程评估新领域做出了贡献。
相似文献
引用本文的文献
Patient Prefer Adherence. 2020-2-27
Pilot Feasibility Stud. 2019-11-8
J Community Med Health Educ. 2018
本文引用的文献
Cochrane Database Syst Rev. 2016-2-20
Glob J Health Sci. 2015-9-1